GLPwatch
Papers (10382)
Page 120 of 174, ranked by citation count.
- Real-world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre-diabetes.
- Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.
- Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.
- Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
- GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.
- Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System.
- Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects.
- Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
- Exendin-4 Induces Cytotoxic Autophagy in Two Ovarian Cancer Cell Lines through Inhibition of Mtorc1 Mediated by Activation of AMPK and Suppression of Akt.
- Acquisition of absorption-enhancing abilities of cationic oligopeptides with short chain arginine residues through conjugation to hyaluronic acid.
- Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report.
- Contractile effects of retatrutide in isolated mouse atrial preparations.
- Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide.
- Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus.
- The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.
- Successful Treatment of Hypothalamic Obesity with Tirzepatide.
- Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity.
- Combination therapy with Exendin-4 and islet transplantation as a synergistic treatment for diabetic nephropathy in rats.
- [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
- Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
- The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
- Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling.
- Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
- Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line.
- Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.
- Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.
- Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.
- Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells.
- Incretin mimetics for weight loss forgive nonadherence.
- Management of obesity.
- Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.
- New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.
- [Injection of submandibular gland with recombinant Exendin-4 and adeno-associated virus for the treatment of diabetic rats].
- Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.
- Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
- Improvement of liraglutide release from PLGA microspheres by a porous microsphere-gel composite system.
- Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.
- Treatment of obesity with GLP-1 receptor agonist after bariatric surgery: Real-world evidence.
- Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.
- Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management.
- Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
- Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.
- Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.
- Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.
- Time to unshackle the medical treatment of obesity in the NHS.
- Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.
- Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
- Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?
- The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment.
- Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.
- Developing a novel exenatide-based incretin mimic (αB-Ex): Expression, purification and structural-functional characterization.
- Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.
- Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.
- Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).
- Use of PASEF for Accelerated Protein Sequence Confirmation and De Novo Sequencing with High Data Quality.
- Current updates on pharmacological roles of glucagon-like peptide 1 in obesity.
- Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.
- GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.
- Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
- Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.